A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Orally Administered PWT33597 Mesylate in Subjects With Advanced Malignancies.
Phase of Trial: Phase I
Latest Information Update: 24 Oct 2012
At a glance
- Drugs PWT 33597 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Biomarker
- 01 Sep 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 25 Oct 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 03 Aug 2011 Additional lead trial centre, investigator identified as reported by ClinicalTrials.gov.